Model Medicines Selected to Participate at the 5th Annual Evercore ISI HealthCONx Conference

LA JOLLA, CA — Model Medicines, the pharmatech company working to transform the drug discovery and development industry and accelerate the creation of life-changing drugs using artificial intelligence (AI) and machine learning (ML), today announced that the company has been invited to participate in the 5th Annual Evercore ISI HealthCONx Conference. Model Medicines will present along with other AI-drug discovery companies like Atomwise and Exscientia, as well as larger pharma companies like Pfizer, Gilead, GSK, and AbbVie, among others.

This announcement follows recent positive data from the Company’s newly created Oncology program and previously announced Infectious Disease program. In this new program, Model Medicines identified multiple AI-discovered compounds demonstrating drug-like activity for two high value, difficult to drug, oncogenic and epigenetic targets. In Q2 of this year, Model Medicines announced that its AI-discovered lead compound, MDL-001, developed in collaboration with world-renowned researchers at Scripps Research and the Icahn School of Medicine at Mount Sinai, demonstrated preclinical proof-of-concept and first-in-class, best-in-class characteristics as a potential broad spectrum infectious disease therapeutic. Since 2019, Model Medicines has announced more than 90+ assets for 10+ targets. 

Dr. Daniel Haders, founder and CEO of Model Medicines will be participating in this year’s  Evercore ISI HealthCONx Conference, presenting data surrounding their four drug programs of infectious disease, oncology, gastrointestinal motility, and inflammation and rare disease.